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DOI 10.1016/j.ccr.2012.02.017SUMMARYLittle is known about the dynamics of cancer cell death in response to therapy in the tumor microenviron-
ment. Intravital microscopy of chemotherapy-treated mouse mammary carcinomas allowed us to follow
drug distribution, cell death, and tumor-stroma interactions. We observed associations between vascular
leakage and response to doxorubicin, including improved response in matrix metalloproteinase-9 null
mice that had increased vascular leakage. Furthermore, we observed CCR2-dependent infiltration ofmyeloid
cells after treatment and thatCcr2 null host mice responded better to treatment with doxorubicin or cisplatin.
These data show that the microenvironment contributes critically to drug response via regulation of vascular
permeability and innate immune cell infiltration. Thus, live imaging can be used to gain insights into drug
responses in situ.INTRODUCTION
One of the major challenges in treating cancer is resistance to
therapy. It is well appreciated that cancer cell intrinsic factors,
such as genetic or epigenetic changes, can cause development
of therapy resistance (Dean et al., 2005). Extrinsic factors in the
microenvironment of certain organs, such as the bone marrow
and thymus, can also confer resistance (Gilbert and Hemann,
2010; Meads et al., 2009). In these cases, resistance is mediated
by factors secreted from stromal cells, such as IL-6. In addition,Significance
It is well appreciated that intrinsic factors regulate chemorespo
extrinsic factors within the microenvironment support the deve
and the inflammatory response. These results have clinical im
breast tumors after chemotherapy and the cellular composit
survival. Our data suggest that the response to classical chem
microenvironment with agents that modifymatrix metalloprotei
observing the tumor response in real-time at cellular resolutio
488 Cancer Cell 21, 488–503, April 17, 2012 ª2012 Elsevier Inc.impaired drug penetration through the extracellular matrix (ECM)
influences drug response in primary solid tumors (Loeffler et al.,
2006; Olive et al., 2009).
Surprisingly little is known about how cells in intact tumors
respond to classical chemotherapies (Minchinton and Tannock,
2006; Rottenberg et al., 2010). Most of the knowledge about
these responses has been obtained from cell culture or xeno-
graft experiments, where cancer cells grow under conditions
very different from the microenvironment of human tumors.
Indeed, such experiments are often not predictive of drugnsiveness. Using in vivomicroscopy of tumors, we show that
lopment of chemoresistance by regulating drug distribution
plications, as myeloid cell infiltration is increased in human
ion of the immune infiltrate is a strong predictor of overall
otherapeutic drugs can be improved by changing the tumor
nase activity and chemokine signaling. Our study shows that
n can yield insights into the biology of chemoresistance.
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Visualizing Host Contribution to Chemoresistanceresponses in patients (Johnson et al., 2001; Minchinton and Tan-
nock, 2006).
To investigate the role of the microenvironment in chemore-
sponsiveness, we chose a well-documented mouse model, the
mammary tumor virus (MMTV) promoter-driven polyoma middle
T oncogene (PyMT) model, that displays progressive stages of
tumorigenesis similar to human luminal type B breast cancer
(Herschkowitz et al., 2007; Lin et al., 2003). As MMTV-PyMT
tumors progress, cancer cells undergo molecular changes,
including increased expression of ErbB receptor family
members (Lin et al., 2003). In parallel, the stromal microenviron-
ment undergoes changes in blood vessel architecture, ECM
composition, and immune cell infiltration (Egeblad et al., 2008,
2010).
RESULTS
Doxorubicin Induces Necrotic Cell Death In Vivo
Doxorubicin (Adriamycin) is a cytotoxic drug used to treat
advanced breast cancer (Rouzier et al., 2005). To investigate
the acute, cellular response to doxorubicin treatment in the
context of the tumormicroenvironment, wemonitoredmammary
carcinomas in live mice using spinning disk confocal microscopy
(Egeblad et al., 2008). MMTV-PyMT mice were crossbred with
the ACTB-ECFP and c-fms-EGFP reporter mice to enable
visualization of different tumor stages and tracking of the most
abundant stromal cell type, myeloid cells (Egeblad et al., 2008).
Dead cells were labeled with propidium iodide (PI) administered
intraperitoneally (i.p.). Cell death became apparent 24–30 hr after
doxorubicin administration and increased as imaging continued,
whereas there was limited cell death in untreated control mice
(Figure 1A; Figure S1A available online; see Figure 2 for quantifi-
cation). The death of individual cells was readily observed as the
appearance of PI staining (Figure 1B; Movie S1). In addition to
cell death in the tumor mass, we observed stromal cell death
(Figure 1A).
Necrosis is a major pathway of cell death after doxorubicin
treatment in vitro (Obeid et al., 2007). Cell death by apoptosis
and necrosis are characterized by specific changes in nuclear
morphology and plasma membrane integrity (Dive et al., 1992).
We next determined the nature of doxorubicin-induced cell
death in vivo by imaging changes in nuclear morphology in
MMTV-PyMT;ACTB-ECFPmice crossbredwithmice expressing
histone H2B conjugated to EGFP (Hadjantonakis and Papaioan-
nou, 2004). The majority of the nuclei became positive for PI
before their morphology changed, indicating early loss of plasma
membrane integrity and necrosis-like cell death. A small
percentage of cells died with breakdown of chromatin into
condensed bodies followed by acquisition of PI labeling, indi-
cating late loss of plasma membrane integrity and apoptosis-
like cell death (Figures 1C and 1D; Movie S2). By histology, we
observed only a minor increase in the number of cells with the
condensed chromatin that is typical of apoptosis after doxoru-
bicin treatment (Figure S1B). Thus, doxorubicin predominantly
induces necrosis in vivo.
Doxorubicin Sensitivity Changes with Tumor Stage
At the macroscopic level, doxorubicin treatment reduced tumor
volume in MMTV-PyMT mice bearing multiple tumors (Figures2A and S2A). However, the smallest or largest tumors tended
to be resistant (Figure S2B), suggesting that resistance was
associated with tumor progression.
MMTV-PyMT tumors have been classified into four patholog-
ical stages, based on cellular morphology, lack of basement
membrane, and infiltration of immune cells (Lin et al., 2003).
We adapted this classification to allow a simplified assess-
ment of tumor stage in live animals: ‘‘hyperplasia,’’ small lesions
showing increased accumulation of cells as compared to
normal epithelium; ‘‘early carcinoma,’’ lesions with evidence
of myeloid cell infiltration and/or cancer cell invasion; and
‘‘late carcinoma,’’ large lesions with densely packed cancer
cells (Egeblad et al., 2008). MMTV-PyMT mammary glands
have multiple tumors, which are often at different stages of
progression. This allowed us to image doxorubicin response
at different stages in the same mouse (Figures 2B and S2C).
Cell death increased after doxorubicin-treatment in early carci-
nomas (Figure 2C); on average, 10% of the fields of view (FOV)
were positive for PI at 31 hr after doxorubicin-treatment
compared to 2% of the FOV in the controls (Figure S2D). In
contrast, cell death did not increase in hyperplasias and late
carcinomas after treatment (Figures 2B, 2C, S2C, and S2D;
Movie S3), suggesting marked differences in drug sensitivity
between tumor stages. Cancer cells in early carcinomas also
accumulated more DNA damage after doxorubicin treatment
than those in hyperplasias or late carcinomas, as determined
by immunostaining for histone g-H2AX (Figure 2D). Thus,
doxorubicin sensitivity changes with tumor stage but not in a
linear manner.
Cancer Cell Proliferation Does Not Correspond
to Doxorubicin Sensitivity In Vivo
Doxorubicin intercalates into DNA, inhibiting topoisomerase II.
Hence, proliferating cells are predicted to be more sensitive
than resting cells (Campiglio et al., 2003). Yet, cancer cell prolif-
eration differed insignificantly between tumor stages (Figure 2E).
Furthermore, in pulse-chase experiments, the percentage of
dead cells that were BrdU+was similar in doxorubicin- and phos-
phate buffered saline (PBS)-treated tumors (Figure 2F). These
data suggest that differences in cellular proliferation between
tumor stages are not the main cause of differences in doxoru-
bicin sensitivity in vivo.
Primary Cancer Cells from Different Tumor Stages Do
Not Exhibit Intrinsic Differences in Doxorubicin
Sensitivity in Culture
As tumors progress, cancer cells acquire mutations and silence
or activate genes. These changes can give rise to differences in
sensitivity between tumor stages. To distinguish the contribution
of cancer cell intrinsic changes from those of the tissue microen-
vironment, we isolated cancer cells from MMTV-PyMT;
ACTB-ECFP mice using a fluorescent dissection microscope.
This allowed us to visualize the cancer epithelium during tissue
removal, ensuring that tumors were representative of the
different stages (Figure S2E). Indeed, in vitro sensitivity to the
ErbB1/ErbB2 inhibitor lapatinib was highest for cells isolated
from late carcinomas (Figure 2G), as predicted from the
increased expression of the ErbB2/Neu oncoprotein in late-
stage tumors (Lin et al., 2003). In contrast, cells from hyperplasia,Cancer Cell 21, 488–503, April 17, 2012 ª2012 Elsevier Inc. 489
Figure 1. Visualizing Cellular Responses to Chemotherapy In Vivo
(A) Doxorubicin-induced cell death in tumors of live MMTV-PyMT;ACTB-ECFP;c-fms-EGFPmice. Induction of cell death (red), visualized by propidium iodide (PI)
uptake, can be seen in a tumor lesion (blue) infiltrated with myeloid cells (green). Red arrows point to cell death in the tumor, and white arrows point to cell death in
the stroma. Time after treatment (doxorubicin) or initiation of imaging (control) is indicated. Scale bar: 100 mm.
(B) Dynamics of cell death in situ. Single cell death was observed as the appearance of PI staining (red arrow). This was followed by myeloid cell infiltration (white
arrows). Time after doxorubicin treatment is indicated. Scale bar: 10 mm.
(C) Dynamics and types of nuclear structural changes after doxorubicin treatment in MMTV-PyMT;ACTB-ECFP;H2B-EGFP mice. Examples of necrosis-like
(nucleus becomes PI+ without major structural changes) and apoptosis-like (nuclear structure breakdown before PI uptake) cell death. Time after treatment is
indicated. Scale bar: 10 mm.
(D) Doxorubicin induces necrosis-like cell death (mean ± SEM; 18 fields of view [FOV] from three mice were counted; p = 0.009 at 32 hr, p < 0.001 at 42 hr,
Student’s t test).
Also see Figure S1 and Movies S1 and S2.
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Visualizing Host Contribution to Chemoresistanceearly carcinoma, and late carcinoma stages had similar sensi-
tivity to doxorubicin in both two- and three-dimensional cultures
(Figures 2H, 2I, and S2F). Primary macrophages and the macro-
phage cell line RAW 264.7 were also sensitive to doxorubicin
(Figure S2G), in accordance with the stromal cell death observed
by imaging. Taken together, the in vitro data indicated that
cancer cell intrinsic mechanisms are unlikely to be responsible
for the differences in doxorubicin sensitivity that were observed
between tumor stages and that extrinsic mechanisms are oper-
ative in vivo.
Visualization of Drug Distribution in Real-Time Reveals
Its Association with Drug Response
Interstitial fluid pressure is one extrinsic factor that increases
in late-stage tumors as compared to early stages and it490 Cancer Cell 21, 488–503, April 17, 2012 ª2012 Elsevier Inc.hinders drug penetration into tumors (Hagendoorn et al.,
2006; Netti et al., 1999). Therefore, we hypothesized that
differences in drug response between tumor stages might be
related to differences in drug accessibility. Doxorubicin is
naturally fluorescent, allowing for imaging of its distribution.
However, its broad emission and excitation spectra overlap
with those of our fluorescent reporters. It was therefore not
possible to image doxorubicin distribution in MMTV-PyMT;
ACTB-ECFP mice in which tumor stage could be determined.
Instead, we imaged unlabeled MMTV-PyMT mice and identi-
fied tumor areas by palpation and abnormal tumor vascula-
ture, visualized using intravenously (i.v.) injected fluorescent
nanoparticles (AngioSPARK 680).
We imaged small (just palpable), medium (160 mm3), and
large (845 mm3) tumors (Figure 3A; Movies S4 and S5).
Cancer Cell
Visualizing Host Contribution to ChemoresistanceDoxorubicin rapidly leaked out into the tissue and accumulated
in the nuclei of cells near blood vessels (Figure 3A). This resulted
in an intravascular half-life of 9.5 min (range, 7.9–11.8 min; Fig-
ure 3B), consistent with the initial plasma half-life of 8.5 min
(range, 7.2–9.8 min) reported in human patients (Greene et al.,
1983). Doxorubicin distribution varied among tumors of different
sizes (Figures 3A and 3C), with the most leakage in larger tumors
and the least leakage in those that were just palpable. Further-
more, significantly more doxorubicin was extractable from small
tumors (13–81 mm3) than from hyperplastic MMTV-PyMT
tissues or normal mammary glands (Figure 3D). Solid tumors
tend to have progressed further than softer ones, and when
tumors were analyzed based on consistency, as well as size,
the highest levels of doxorubicin were found in soft tumors,
although the values were not significantly higher than in solid
tumors of similar size (Figure 3E).
Tumor size and consistency is not an accurate indicator of
tumor stage. Thus, to quantify vascular leakage in tumors of
different stages, we co-injected i.v. fluorescent 10 kD (low) and
2 MD (high) molecular mass dextrans into MMTV-PyMT;ACTB-
ECFP mice (Figures 4A and S3A; Movie S6). The intravascular
half-lives of dextrans were similar in tumor microenvironments
at different stages (Figures S3B and S3C), with a higher intravas-
cular half-life for 2 MD dextran (41 [range, 32–58] min) than for
10 kD dextran (15 [range, 14–16] min; Figure S3D).
In contrast to intravascular half-life, leakage of dextrans into
the extravascular space and their retention in tissues were
clearly influenced by tumor stage (Figures 4A and 4B). Regions
with hyperplasias showed limited leakage into the extravascular
space, whereas early carcinomas and the tumor-stroma borders
of late carcinomas exhibited substantially more leakage. Ex-
travasated 10 kD dextran reached a larger area of the tissue
than did extravasated 2 MD dextran (Figures 4A and 4B).
Following extravasation, the dextrans accumulated in stromal
cells, which we have previously shown are c-fms+CD68+CD206+
macrophages (Egeblad et al., 2008). Leakage in normal
mammary glands was minimal and below detection limits
when the settings used for tumor-bearing mice were applied
(not shown).
Finally, we co-injected i.v. doxorubicin-treated mice with
10 kD dextran and Ricinus communis agglutinin I, a lectin that
binds to basement membrane exposed to the vascular lumen,
marking leaky vasculature (Thurston et al., 1999). We observed
that only tumor areas in close proximity to these two markers
contained cells with nuclear uptake of doxorubicin (Figure S3E).
Interestingly, some of the cells with doxorubicin-positive nuclei
had also taken up dextran, suggesting that they were macro-
phages (Figure S3E).
Absence of MMP9 Results in Increased Vascular
Leakage and Sensitizes Tumors to Doxorubicin
Treatment
Tumor-associated macrophages promote vascular changes
(Egeblad et al., 2010). We found that the extent of local c-fms-
EGFP+ myeloid cell infiltration correlated significantly with the
degree of local 10 kD dextran leakage, regardless of tumor stage
(Figures 4C and 4D). Myeloid cells can regulate vessel stability
via secretion of vascular endothelial growth factor (VEGF) and
transforming growth factor (TGF)-b, both of which are seques-tered in the ECM and released by matrix metalloproteinases
(MMPs; Yu and Stamenkovic, 2000; Ebrahem et al., 2010).
Nevertheless, MMPs may also negatively regulate vascular
permeability (Sounni et al., 2010). Several MMPs, including
MMP9, are expressed at high levels by tumor-infiltrating myeloid
cells (Figure 5A). To determine if host-derived MMP9 affects
vascular stability and doxorubicin response, we transplanted
MMTV-PyMT cancer cells to wild-type FVB/n and Mmp9/
hosts and treated them with doxorubicin. Although MMP9
does not influence primary tumor growth in the transgenic
MMTV-PyMT model (Martin et al., 2008), we found that the
growth of grafted tumors was reduced in Mmp9/ hosts
compared to FVB/n hosts (Figure S4A). Interestingly, tumors in
Mmp9/ hosts responded better to doxorubicin than those in
FVB/n hosts (Figure S4B).
Since transplanted MMTV-PyMT tumors grew slower in
Mmp9/ hosts, we could not rule out that the influence of
MMP9 on doxorubicin response was related to its effects on
cancer cell proliferation. Therefore, we tested if MMP9 influ-
enced the response in the MMTV-Neu model, another doxoru-
bicin-sensitive, luminal breast cancer model, in which the
absence of MMP9 does not affect cancer cell proliferation or
tumor growth (Figures S4C and S4D; data not shown). Vascular
volume, determined by i.v. tomato lectin staining, was not
affected by MMP9 status, but tumor vessels were leakier in the
absence of MMP9, as determined by i.v. staining with Ricinus
communis agglutinin I (Figures 5B–5D). In the absence of
MMP9, the endothelial cell adhesion molecule VE-cadherin
showed increased phosphorylation (Figures 5E and 5F), which
results in loose adherence junctions (Gavard, 2009). Vascular
coverage with pericytes, which support endothelial cells, was
also decreased (Figures 5G and S4E). In keeping with the
increased permeability of the vasculature, MMTV-Neu;Mmp9/
tumors treated with doxorubicin responded better than did
MMTV-Neu;Mmp9+/+ tumors (Figure 5H). In contrast, C3(1)-
Tag tumors, a basal-like mammary carcinoma model that is
largely doxorubicin-resistant (Figure S4F), did not respond better
in the absence of MMP9 (Figure S4G).
Doxorubicin Treatment Leads to Recruitment ofMyeloid
Cells to Tumors
We observed that vascular leakage was associated with higher
infiltration of macrophages (Figure 4D), so we sought to deter-
mine the effect of MMP9 on macrophage infiltration. There
were increased numbers of cells expressing the F4/80 and
CD206 macrophage markers in untreated tumors of Mmp9/
hosts compared to those of FVB/n hosts (Figures 6A and 6B).
Interestingly, doxorubicin treatment significantly reduced the
number of macrophages in Mmp9/ hosts, suggesting that
macrophages were killed.
Despite the reduction in macrophage numbers observed after
doxorubicin-treatment of Mmp9/ hosts, imaging consistently
showed recruitment of myeloid cells to doxorubicin-treated
tumors in wild-type mice (Figures 6C and 6D; Movie S7). These
myeloid cells often formed granuloma-like structures in areas
with cell death (Movie S7). Rarely, we observed myeloid cell
recruitment prior to cancer cell death (Figure S5A).
Myeloid cells are a diverse family of innate immune cells,
including neutrophils, monocytes, and macrophages, that areCancer Cell 21, 488–503, April 17, 2012 ª2012 Elsevier Inc. 491
Figure 2. Doxorubicin Sensitivity Changes with Tumor Stage In Vivo but Not In Vitro
(A) Doxorubicin treatment reduces tumor volume in MMTV-PyMT mice. Mice were given doxorubicin or PBS at days 0, 7, and 14 (indicated by arrows). Analysis
includes 73 tumors from eleven doxorubicin-treated mice and 56 tumors from 12 PBS-treatedmice (mean ± SEM, p < 0.0001 for all time-points, Student’s t test).
(B) Doxorubicin-induced cell death preferentially occurs in early carcinomas and not in hyperplasias and late carcinomas. Different microenvironments imaged in
the same MMTV-PyMT;ACTB-ECFP;c-fms-EGFP mouse after doxorubicin treatment. Time after treatment is indicated. Scale bar: 100 mm.
(C) Cell death increases between 24 and 36 hr after doxorubicin treatment (n = 25 fields of view [FOV]) as compared to control mice imaged for similar time frames
(n = 23 FOV; Fisher’s exact test; p = 0.001). Cell death increases in early carcinomas (12 of 14 doxorubicin-treated versus 1 of 8 control-treated FOV, Fisher’s exact
test, p=0.002)butnot inhyperplasias (1of 4 versus1of8fields)or latecarcinomas (3of7 versus2of7). Fourcontrol- and fourdoxorubicin-treatedmicewere imaged.
(D) DNA damage response measured by g-H2AX immunostaining differs between tumor stages (mean ± SEM, analysis of variance [ANOVA], p < 0.0001) and is
higher in early carcinomas than in hyperplasia (p < 0.01, Bonferroni posttest) or late carcinomas (p < 0.0001; Bonferroni posttest; 21 hyperplasia, 25 early
carcinoma, and 24 late carcinoma FOV were evaluated in five tumors from five mice).
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determine a basis for myeloid cell infiltration, we injected
necrotic cell debris into mammary glands of non-tumor-bearing
mice and imaged the response. In this model, the results are
independent of any direct effects of doxorubicin on myeloid
cells, such as induction of cell death. Myeloid cell infiltration
increased in areas injected with necrotic debris as compared
to areas injected with only saline and dextran (Figure S5B).
Once a myeloid cell recognized the cell debris, other myeloid
cells were rapidly recruited and a granuloma-like structure was
formed (Figure S5B; Movie S8). Myeloid cell recruitment is often
mediated by Gi-protein-coupled chemokine receptors (Sadik
et al., 2011). Mice pretreated with pertussis toxin, a Gi-protein
inhibitor, showed reducedmyeloid cell recruitment to cell debris,
suggesting the involvement of chemokine receptors in this
process (Figure S5C; Movie S9).
Myeloid Cells Are Recruited to Doxorubicin-Treated
Tumors through a Stromal CCL2/CCR2 Chemokine/
Chemokine Receptor Axis
To screen for candidate chemokines involved in the recruitment
of myeloid cells, we used a protein array. Tumor lysates iso-
lated 48 hr after doxorubicin treatment showed increased
protein levels for CCL2 and CCL12 (Figure 7A). Both of these
chemokines are ligands for the CCR2 receptor, which is ex-
pressed on monocytes and is responsible for their recruitment
to sites of inflammation (Tsou et al., 2007). We also observed
small increases in macrophage colony-stimulating factor
(M-CSF/CSF1) and tissue inhibitor of metalloproteinase 1
(TIMP1; Figure 7A). We confirmed the increases in CCL2 and
CCL12 by enzyme-linked immunosorbent assay and immuno-
staining (Figures 7B, S6A, and S6B). CCL2-expressing cells
were large cells located in the stroma that did not express
markers of fibroblasts and pericytes (Figure 7C) or endothelial
cells (Figure 7D).
Next, we investigated the types of myeloid cells recruited after
doxorubicin treatment. Infiltration of cells expressing a neutro-
phil/monocyte marker, the 7/4 antigen (Ly6B.2), was signifi-
cantly increased (Figure 7E). This increase was exclusively
found among cells that also expressed the CCL2 receptor,
CCR2, and had a monocytic nuclear morphology (Figures 7E
and S6C). The number of 7/4+CCR2 cells did not increase
but rather decreased, after doxorubicin treatment (Figure 7E).
A small number of CCR2+ cells did not express the 7/4 antigen,
but their numbers did not change after doxorubicin treatment
(Figure 7E). In contrast to the acute increase in the infiltration
of 7/4+CCR2+ cells, overall macrophage infiltration, as deter-
mined by the F4/80 marker, was not changed 48 hr after doxo-(E) Cancer cell proliferation determined by BrdU labeling does not differ between
13 hyperplasia, 19 early carcinoma, and 28 late carcinoma FOV were evaluated
(F) Proliferating (BrdU+) cells are not preferentially killed by doxorubicin treatmen
scored (mean ± SEM, n.s., Student’s t test; for each condition, 58–60 FOV were
(G) Sensitivity to the ErbB1/ErbB2 inhibitor lapatinib is highest for cancer cells f
Student’s t test; values represent the averages of four experiments, each done i
(H) Sensitivity to doxorubicin is not affected by tumor stage in culture (mean ± SEM
triplicate with primary cells from independent mice).
(I) Morphology of organoids generated from tumors at different stages after trea
Also see Figure S2 and Movie S3.rubicin treatment (Figure S6D). However, a small increase was
seen in the number of cells within the tumor mass that ex-
pressed CD206, a marker of alternatively activated macro-
phages (Figure S6E).
We next tested whether CCR2 mediates the myeloid cell infil-
tration seen after doxorubicin treatment. We transplanted
primary cancer cells isolated fromMMTV-PyMTmice to Ccr2/
or C57BL/6 hosts and characterized the myeloid cell population
after doxorubicin treatment. In C57BL/6 hosts, the fraction of
cells co-expressing the myeloid cell marker CD11b with the
monocyte/neutrophil markers Gr1 and 7/4 increased signifi-
cantly after doxorubicin treatment (Figures 7F and 7G). The total
proportion of cells in the tumors that expressed the myeloid
CD11b marker did not increase (Figure S6F). Tumors of Ccr2/
hosts had a higher fraction of CD11b+7/4+Gr1+ cells than did
C57BL/6 hosts (Figures 7F and 7G), consistent with previous
reports (Pahler et al., 2008). However, there was no significant
increase in this cell population after doxorubicin treatment in
Ccr2/ hosts (Figures 7F and 7G). Doxorubicin treatment did
not affect the subpopulations of CD11b+ cells that expressed
F4/80 or CXCR4 in either genotype (Figures S6G—S6I).
Together, our results suggest that doxorubicin treatment leads
to a specific, acute recruitment of CCR2-expressing myeloid
cells of the monocytic lineage through stromally expressed
CCL2.
Host CCR2 Influences Tumor Response to
Chemotherapy
To determine if CCR2-mediated recruitment of myeloid cells
influenced the response to doxorubicin, we generated cohorts
of MMTV-PyMT;Ccr2+/ and MMTV-PyMT;Ccr2/ mice. For
doxorubicin-sensitive tumors (250–750 mm3), the absence of
CCR2 was associated with a significantly better response,
although tumors in both cohorts ultimately relapsed (Figure 8A).
In contrast, tumors below 250 mm3, which respond poorly to
doxorubicin, did not show a better response to treatment when
mice were deficient for CCR2 (Figure S7A).
CCL2 has been proposed to promote cancer cell survival
through CCR2 receptors on cancer cells (Zhang et al., 2010).
To rule out the involvement of CCR2 signaling in cancer cells,
we transplanted primary cancer cells from MMTV-PyMT mice
to Ccr2/ or C57BL/6 hosts. When treated with doxorubicin
or cisplatin, a different class of chemotherapeutic drug with effi-
cacy against MMTV-PyMT tumors (Figure S7B), tumors in
Ccr2/ hosts relapsed later than those in C57BL/6 hosts
(Figures 8B and 8C). Tumor growth before treatment was not
significantly different between Ccr2/ and C57BL/6 hosts (Fig-
ure 8B). Myeloid cells can secrete factors that increase cancertumor stages in MMTV-PyMT mice (mean ± SEM, not significant, n.s., ANOVA;
in six tumors from three mice).
t. The fraction of BrdU+ cells with cell death-associated nuclear changes was
analyzed in six tumors from three mice).
rom late-stage tumors in culture (mean ± SEM, p = 0.04 or 0.02 as indicated,
n triplicate with primary cells from independent mice).
, n.s., ANOVA; values represent the averages of four experiments, each done in
tment with the indicated concentrations of doxorubicin. Scale bar: 50 mm.
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Figure 3. Distribution and Uptake of Doxorubicin in Different Tumor Sizes
(A) Doxorubicin leakage and uptake vary with tumor size. MMTV-PyMT mice with small (just palpable tumors), medium (160 mm3), or large tumors (845 mm3)
were injected intravenously with AngioSPARK 680 (green) and doxorubicin (red). Minimal leakage and uptake were seen in small tumors. Leakage was high in
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survival benefit on primary cancer cells when they were cultured
with primary macrophages (Figures S7C and S7D).
Although tumors in Ccr2/ hosts relapsed, they were of
a strikingly lower histological grade than the high-grade relapsed
tumors of C57BL/6 hosts (Figure 8D). Histological differences
were already evident 48 hr after doxorubicin treatment as tumors
in Ccr2/ hosts were more cystic than those in C57BL/6 hosts
(Figure 8D). Taken together, our data suggest that infiltration of
CCR2-expressing myeloid cells into chemotherapy-treated
tumors contributes to tumor regrowth after treatment.
Like CCR2, MMP9 can also influence myeloid cell recruitment
(Gong et al., 2008). We therefore tested whether the effects of
MMP9 on doxorubicin response could be explained by effects
on the acute recruitment of myeloid cells to treated tumors.
However, adaptively transferred bone marrow cells from
c-fms-EGFP;Mmp9+/+ and c-fms-EGFP;Mmp9/mice were re-
cruited equally well to tumors of MMTV-PyMT mice after treat-
ment with doxorubicin (Figure S7E). Next, we tested whether
the changed myeloid cell environment in Ccr2/ mice corre-
lated with vascular changes, akin to the effects of loss of
Mmp9 (Figure 8E). Whereas the vascular volume was higher in
tumors of Ccr2/ mice (Figure 8F), the percentage that was
leaky was significantly lower, with the net result being no change
in the total volume of leaky vasculature (Figures 8G and 8H).
Furthermore, pericyte coverage of the vasculature was
increased in Ccr2/ hosts, whereas VE-cadherin phosphoryla-
tion levels were unaffected (Figures S7F–S7I). Thus, although the
response to doxorubicin is improved in both Mmp9/ and
Ccr2/ microenvironments, the effects on vascular structure
and myeloid cell recruitment after treatment are different.
DISCUSSION
We imaged the dynamics of doxorubicin responses in a progres-
sive cancer model and revealed that chemosensitivity in vivo is
influenced by the tumor microenvironment. The highest sensi-
tivity to doxorubicin was not observed in the earliest or latest
tumor stages but rather in the intermediate stage. These differ-
ences in drug response between stages were associated with
parallel differences in vascular leakage. We therefore tested
doxorubicin response in Mmp9 null tumor microenvironments
with increased vascular permeability and found an improved
response. Doxorubicin treatment led to the recruitment of
CCR2+ monocytic cells to tumors. In Ccr2 null microenviron-medium and some large tumors, with variable nuclear retention. Time after doxo
rubicin (higher magnification of the areas outlined in the fourth column). Scale ba
(B) Decay of intravascular doxorubicin levels determined by imaging is modeled
mice were analyzed).
(C) Kinetics of doxorubicin leakage from vessels in tumors of different sizes. Quant
intensity threshold (150% of background) and as a ratio of extravascular doxorub
FOV were analyzed in six mice).
(D) Doxorubicin concentration is higher in tumors than hyperplasias and norma
posttests for comparison of groups; p < 0.05 or n.s. as indicated; ten normal
[13–81 mm3] from five MMTV-PyMT were analyzed).
(E) Doxorubicin concentration is higher in tumors that were soft upon dissection t
0.01, ANOVA, and Bonferroni posttests for comparison of groups, p < 0.01 or 0.0
solid and medium-sized (60–350 mm3), and 21 solid and large tumors (351–1,40
Also see Movies S4 and S5.ments, recruitment was inhibited and the response to chemo-
therapy better. These results have clinical implications, as
myeloid cell infiltration is increased in human breast tumors after
chemotherapy and the composition of the immune infiltrate is
a predictor of survival (Denardo et al., 2011).
Stromal Regulation of Vascular Leakage
Primary cancer cells from different stages responded similarly
to doxorubicin in vitro, whereas doxorubicin sensitivity, tumor
stage, and vascular leakage were related in vivo. This suggests
that stage-specific changes in vascular leakage contributed to
doxorubicin response although we cannot exclude contribu-
tions from stromal cells. Strikingly, increased leakage of the
tumor vasculature in Mmp9/ mice corresponded to a better
response to doxorubicin. The increased vascular permeability
in Mmp9/ mice was associated with decreased pericyte-
coverage of the vasculature and increased phosphorylation
of VE-cadherin, which affect endothelial cell-cell adhesions
(Gavard, 2009; Goel et al., 2011). Although MMP inhibitors
have failed in clinical trials (Coussens et al., 2002), our data
suggest that these, or other drugs that affect vascular perme-
ability, could be used to achieve better responses to
chemotherapies.
MMP9 may regulate vascular structure by acting on
a substrate in the tumor microenvironment. Indeed, a reduction
of infiltrating MMP9+ myeloid cells through inhibition of the
CSF-1 receptor results in a better response to anti-VEGFR2
treatment (Priceman et al., 2010). However, MMP9 may also
regulate vascular permeability indirectly through its effects on
macrophage infiltration. Macrophages can secrete VEGF (also
known as vascular permeability factor), which induces VE-cad-
herin phosphorylation in endothelial cells (Gavard, 2009).
Myeloid cells are not the only stromal cells capable of regu-
lating drug delivery in tumors. By decreasing the fibroblast
pool, and thus the ECM, drugs better enter the tissue (Loeffler
et al., 2006; Olive et al., 2009). Interestingly, the improved drug
delivery in these cases is achieved by increased vascular density
and ‘‘vascular normalization,’’ which involves better pericyte
coverage and reduced permeability (Goel et al., 2011). Since
vascular volume and pericyte coverage increased in tumors of
Ccr2/ compared to C57BL/6 hosts, such vascular changes
could play a role in the MMTV-PyMTmodel. Untangling the roles
of MMP9 and CCR2 on vasculature, myeloid cell infiltration, and
drug response will require the ability to temporally and condition-
ally manipulate these genes.rubicin injection is indicated. The last column shows nuclear uptake of doxo-
r: 100 mm.
as one-phase exponential decay (black line; mean ± SEM; eight FOV from two
ification of the percentage of extravascular pixels with doxorubicin signal above
icin to vascular area (mean ± SEM; eight small, four medium, and eleven large
l mammary glands (means are shown; p < 0.0001, ANOVA, and Bonferroni
mammary glands from five FVB/n mice and 14 hyperplastic and 47 tumors
han in hyperplastic tissue or solid tumors of similar size (means are shown, p =
5 as indicated). Ten hyperplastic, 15 soft and medium-sized (60–350 mm3), ten
0 mm3) from five MMTV-PyMT mice were analyzed.
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Figure 4. Leakage and Distribution of Intravenously Injected Dextran Varies with Tumor Stage
(A) Early carcinomas exhibit a higher degree of dextran leakage than do hyperplasias and late carcinomas. More extensive leakage of 10 kD than 2MD dextran is
shown for all tumor stages. Kinetics of 10 kD (red) and 2 MD dextran (green) leakage from vessels in three different tumor stages from the same MMTV-PyMT;
ACTB-ECFPmouse are shown. Regions with leakage of both dextrans are depicted in white and the epithelium in blue (ACTB-ECFP). Time after dextran injection
is indicated. Scale bar: 100 mm.
(B) Quantification of the percentage of pixels above intensity threshold (150% of background) for the two dextrans in the epithelial and stromal compartments
(mean ± SEM; four hyperplasias from two mice, five early carcinomas from four mice, and five late carcinomas from four mice were analyzed).
(C) The extent of c-fms-EGFP+ myeloid cell infiltration in MMTV-PyMT;ACTB-ECFP;c-fms-EGFP mice and the degree of 10 kD dextran leakage were scored
independently using the indicated pixel grid. Co-injected 2 MD dextran was used to differentiate between intra- and extravascular 10 kD dextran. Examples of
pixel fields scored as maximal infiltration and leakage are indicated by the white boxes. Scale bar: 100 mm.
(D) Myeloid cell infiltration correlates with dextran leakage (r = 0.56 and r = 0.47, for observer A and B, respectively, p < 0.0001, Spearman’s rank correlation
coefficient; 720 FOV from two mice were scored).
Also see Figure S3 and Movie S6.
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Figure 5. Matrix Metalloproteinase-9 Is Expressed by Myeloid Cells and Influences Vascular Leakage and Response to Doxorubicin
(A) MMP9 is expressed by tumor-infiltrating myeloid cells, including those marked by 7/4 (neutrophils/monocytes) and F4/80 (macrophages). Scale bars: 50 mm.
(B) Vascular structure of tumors in MMTV-Neu;Mmp9+/+ andMMTV-Neu;Mmp9/mice analyzed by perfusion with FITC-conjugated tomato lectin (green, labels
all blood vessels) and rhodamine-conjugated Ricinus communis agglutinin I (red, labels basement membrane exposed to the vascular lumen in leaky vessels).
Scale bar: 100 mm.
(C) Vascular volume as determined by perfusion with tomato lectin does not differ between MMTV-Neu;Mmp9+/+ and MMTV-Neu;Mmp9/mice (mean ± SEM,
n.s., Student’s t test, 33 FOV in ten tumors from fiveMMTV-Neu;Mmp9+/+mice and 29 FOV in eight tumors from threeMMTV-Neu;Mmp9/mice were analyzed).
(D) Blood vessels are leakier in MMTV-Neu;Mmp9/ tumors. The percentage of the vasculature that is positive for Ricinus communis agglutinin I is shown
(mean ± SEM, p = 0.004, Student’s t test, 33 FOV in ten tumors from fiveMMTV-Neu;Mmp9+/+ mice and 29 FOV in eight tumors from threeMMTV-Neu;Mmp9/
mice were analyzed).
(E) Immunostaining for phospho-Y731 VE-cadherin. Scale bar: 100 mm.
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Responses
Recruitment of CCR2+ monocytes after doxorubicin treatment
correlated with tumor relapse. Similarly, an increased number
of macrophages is found after treatment of tumors with chemo-
therapy and is associated with poor drug response (Denardo
et al., 2011; Shree et al., 2011). Such macrophages can promote
cancer cell survival through the secretion of cysteine cathepsins
(Shree et al., 2011). CCR2+ monocytes could be the source of
tumor-associated macrophages in the posttreatment microenvi-
ronment. Indeed, we did not observe increased numbers of
macrophages 48 hr after treatment, whereas they have been
observed 7–12 days after the first dose of chemotherapy in the
MMTV-PyMT model (Denardo et al., 2011; Shree et al., 2011).
However, macrophage infiltration depends on CSF-1 (Denardo
et al., 2011). Furthermore, macrophages do not promote survival
of cancer cells in a cathepsin-dependent manner after treatment
with the cisplatin-related drug carboplatin (Shree et al., 2011),
whereas the response to cisplatin was better in Ccr2/ hosts.
Thus, it is possible that CCR2+ monocytes and tumor-associ-
ated macrophages are recruited through independent pathways
and influence drug responses through independent mecha-
nisms. Several such mechanisms likely exist. For example, Tie-
2-expressing macrophages are recruited after hypoxic tissue
injury through a CXCL12/CXCR4 chemokine axis (Welford
et al., 2011).
Our results, as well as those of others (Ahn et al., 2010; De-
nardo et al., 2011; Shree et al., 2011; Welford et al., 2011), indi-
cate that the myeloid cell infiltration that occurs after chemo-
therapy, radiation, or tissue injury impedes the response to
therapy. However, myeloid cell recruitment can also lead to the
direct killing of cancer cells (Guerriero et al., 2011), thereby
increasing the response to chemotherapy. These differences in
the effects of recruited myeloid cells are likely due to the recruit-
ment of different subpopulations of myeloid cells. Indeed, infil-
tration of CD206+ macrophages was associated with increased
vascular leakage and better doxorubicin response, whereas
reduced CCR2-dependent recruitment of monocytic cells was
associated with delayed tumor relapse.
Interestingly, stromal cells expressed CCL2 after doxorubicin
treatment. This offers a possible explanation for the observation
that stromally derived, but not cancer cell-derived, CCL2 is asso-
ciated with decreased relapse-free survival in breast cancer
patients (Fujimotoetal., 2009).Furthermore,administrationofanti-
bodies specific for mouse CCL2 enhances the response to doce-
taxol in a xenograft model of prostate cancer (Loberg et al., 2007).
Conclusions
In vivo imaging of tumors shows that different components
of the microenvironment participate in the development of(F) Depletion of MMP9 increases phosphorylation of VE-cadherin in endothelial ce
MMTV-Neu;Mmp9+/+ mice and 101 vessels from tumors of nine MMTV-Neu;Mm
(G) Pericyte coverage is decreased in the absence of MMP9. Double immunofluor
positive endothelial cells (mean ± SEM, p = 0.002, Student’s t test, 87 vessels from
MMTV-Neu;Mmp9/ mice were examined).
(H) MMTV-Neu;Mmp9/ (n = 7 tumors from five mice) tumors respond better to t
from six mice; mean ± SEM, * indicates p < 0.05; Student’s t test). Tumors below
Also see Figure S4.
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beneficial for the response to doxorubicin and cisplatin. Our
data suggest that existing drugs that inhibit MMPs or chemokine
signaling may be effective when combined with traditional
chemotherapies. However, the order and timing of administra-
tion of such combination therapies could be critical because
of the complexity of the interactions between myeloid cells
and vasculature in chemotherapy responses. Future studies
combining imaging with molecular approaches hold promise
for gaining further insights into the targeting of tumors in the
context of its microenvironment.
EXPERIMENTAL PROCEDURES
Animals
MMTV-PyMT (FVB/n), MMTV-Neu (FVB/n), ACTB-ECFP (FVB/n), ACTB-H2B-
EGFP (obtained on mixed background and backcrossed to FVB/n for six
generations), and Ccr2/ (C57BL/6) mice were from Jackson Laboratory.
MMTV-PyMT (C57BL/6) mice were provided by Dr. Kasper Almholt, and
c-fms-EGFP mice were provided by Dr. Jeffrey Pollard and backcrossed to
FVB/n mice for six generations. Mmp9/ mice (FVB/n) were previously
described (Vu et al., 1998). All animal experiments were conducted in accor-
dance with procedures approved by the IACUC at Cold Spring Harbor Labo-
ratory or the University of California, San Francisco.
Tumor Transplantation Experiments
Virgin females of 6–16 weeks of age were used as hosts for transplantation.
Cancer cells were isolated from 2–3 tumors at 8–10 mm diameter from
MMTV-PyMT mice. Tumors were mechanically dissociated and digested
with collagenase (0.2% w/v), trypsin (0.2% w/v), and DNase I (8 U/ml) in
RPMI-1640 medium. Single cells and debris were removed from the resulting
carcinoma organoid preparation by differential centrifugation. Purified carci-
noma organoids were dissociated into single cell suspension in 0.25%
trypsin with 0.1% ethylene diaminetetraacetic acid (EDTA) and washed in
PBS. Cells (4 3 105 in 20 ml PBS) were injected into the inguinal mammary
glands of host mice.
Tumor Response to Doxorubicin and Cisplatin
Mice received 8 mg/kg doxorubicin hydrochloride (in PBS; Sigma-Aldrich,
St. Louis, MO, USA) or 10 mg/kg cisplatin (in 10% dimethyl sulfoxide in
PBS; MBL International, Woburn, MA, USA) i.p. on days 0, 7, and 14. Control
mice were injected with sterile PBS. Tumors were measured 2–3 times a week
by caliper, and tumor volumes were calculated as length 3 width2/2.
Spinning Disk Confocal Imaging of Live Mice
Details of the microscope design and imaging procedure were previously
described (Egeblad et al., 2008). To track cell death, mice were injected
i.p. with 50 ml/h propidium iodide (PI; 0.05–0.1 mg/ml; Invitrogen, Grand
Island, NY, USA) in sterile PBS. To determine doxorubicin distribution,
MMTV-PyMT mice were injected i.v. with AngioSPARK 680 (100 ml of stock
solution; PerkinElmer, Waltham, MA, USA) and doxorubicin (8 mg/kg body
weight in 200 ml PBS). To determine vascular leakage, mice were injected
i.v. with 100 ml sterile PBS containing 1 mg/ml 10 kD Alexa-Fluor-647-
conjugated dextran and 1 mg/ml 2 MD rhodamine-conjugated dextran
(Invitrogen).lls (mean ± SEM, p < 0.0001, Student’s t test, 113 vessels from tumors of nine
p9/ mice were examined).
escence was used to determine the ratio of aSMA-positive pericytes to CD31-
tumors of ten MMTV-Neu;Mmp9+/+mice and 71 vessels from tumors of nine
reatment with doxorubicin than do MMTV-Neu;Mmp9+/+ tumors (n = 11 tumors
256 mm3 at the beginning of treatment were excluded from the analysis.
Figure 6. Myeloid Cells Are Recruited to Areas of Tumor Necrosis
(A and B) The infiltration of (A) alternatively activated macrophages (n = 40 FOV from tumors of four mice per condition) and (B) the total macrophage population
(n = 22–30 FOV from 4–5 mice per condition) is increased in Mmp9/ host mice transplanted with MMTV-PyMT tumor cells. The infiltration of these cells
decreases 48 hr after doxorubicin treatment (mean ± SEM, n.s. or significant as indicated, Student’s t test).
(C) Myeloid cells are recruited to tumors after doxorubicin treatment (12 of 16 movies) as compared to tumors of PBS-treated control mice (3 of 16 movies, p =
0.004, Fisher’s exact test; three mice were analyzed per condition).
(D) Dynamics of myeloid cell infiltration (arrow) into an area of necrosis in a doxorubicin-treated MMTV-PyMT;ACTB-ECFP;c-fms-EGFP mouse. Time after
treatment is indicated. Scale bar: 100 mm.
Also see Figure S5 and Movies S7, S8, and S9.
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Paraformaldehyde-fixed, paraffin-embedded sections were stained with
Mayer’s hematoxylin and eosin. Immunostaining was done with primary anti-
bodies against 7/4 (Cedarlane, Burlington, NC, USA), BrdU and MECA-32
(Developmental Studies Hybridoma Bank, University of Iowa, Iowa City,IA, USA), CCL2, CD206, and F4/80 (AbD Serotec, Raleigh, NC, USA), CCR2
(Novus Biologicals, Littleton, CO, USA), phospho-histone H2AX and phos-
pho-histone H3 (Cell Signaling, Danvers, MA, USA), aSMA (Sigma-Aldrich),
CD31 and phospho-VE-cadherin (Abcam, Cambridge, MA, USA), and MMP9
(Rasch et al., 2010). Immunostained slides were quantified by countingCancer Cell 21, 488–503, April 17, 2012 ª2012 Elsevier Inc. 499
Figure 7. Myeloid Cells Are Recruited to Doxorubicin-treated Tumors through a Stromal CCL2/CCR2 Chemokine/Chemokine Receptor Axis
(A) Protein array identifies CCL2 as themost upregulated chemokine in tumor lysates 48 hr after doxorubicin treatment (p = 0.09 for CCL2 and p = 0.03 for CCL12,
Student’s t test). Each column represents a tumor from a different mouse.
(B) The number of CCL2-expressing cells increases 48 hr after treatment with doxorubicin (mean ± SEM, p = 0.04, Student’s t test; 80 FOV from six PBS-treated
and 66 FOV from six doxorubicin-treated mice were analyzed).
(C and D) Endothelial cells, pericytes, and fibroblasts do not express CCL2. Tumor tissue fromMTMV-PyMT mice isolated 48 hr after treatment with doxorubicin
was immunostained for CCL2 and (C) a-smooth muscle actin (aSMA, a pericyte, and fibroblast marker) or (D) MECA-32 (an endothelial cell marker). More than
300 aSMA or MECA-32 positive cells from PBS and doxorubicin-treated tumors were observed, and none were positive for CCL2. Scale bar: 50 mm.
(E) Doxorubicin treatment results in infiltration of 7/4+CCR2+ cells with monocytic but not polymorphonuclear (PMN) morphology. Double immunostaining for
CCR2 and 7/4 with scoring of nuclear morphology (mean ± SEM, Student’s t test, significance levels as indicted; 104 FOV from four PBS-treated and 113 FOV
from five doxorubicin-treated mice).
(F) Doxorubicin results in CCR2-dependent myeloid cell infiltration. The percentage of Gr1+7/4+ of all CD11b+ myeloid cells in tumors was determined by flow
cytometry (mean ± SEM, significance levels as indicated, Student’s t test, n = 10–11 mice).
(G) FACS plots with indication of the percentages of the gated cell populations from representative tumors.
Also see Figure S6.
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Figure 8. Host CCR2 Regulates Response to Doxorubicin
(A) Tumors in MMTV-PyMT;Ccr2/ (26 tumors from ten mice) respond better to doxorubicin than those in MMTV-PyMT;Ccr2+/ (15 tumors from eight mice).
Results for tumors with a pretreatment volume of 250–750 mm3 (mean ± SEM, * indicates p < 0.05, Student’s t test).
(B) Tumors in Ccr2/ host mice respond better to doxorubicin than those in C57BL/6 hosts. Two cohorts were treated with doxorubicin and showed similar
results. The results of one cohort are shown (mean ± SEM, * indicates p < 0.05, Student’s t test; eight tumors in 6–8 hosts were analyzed per condition; one
Ccr2/ and two C57BL/6 hosts were euthanized on days 13–16 due to poor health).
(C) Tumors in Ccr2/ hosts respond better to cisplatin than those in C57BL/6 hosts (mean ± SEM, * indicates p < 0.05, ** indicates p < 0.01, Student’s t test, n =
22–24 tumors in 11–12 hosts).
(D) Tumors in Ccr2/ hosts are more cystic and contain fewer cancer cells acutely (48 hr) after doxorubicin treatment. Relapsed tumors (six weeks after
treatment) in Ccr2/ hosts are low-grade with decreased cellularity and necrosis (p = 0.005, Fisher’s exact test; ten low-grade and five high-grade tumors in
Ccr2/ hosts versus one low-grade and eleven high-grade tumors in C57BL/6 hosts). Scale bar: 100 mm.
(E) Vascular structure of tumors in Ccr2/ and C57BL/6 hosts analyzed by perfusion with FITC-conjugated tomato lectin (green) and rhodamine-conjugated
Ricinus communis agglutinin I (red). Nuclei are stained with 40,6-diamidino-2-phenylindole (DAPI). Scale bar: 100 mm.
(F) Vascular volume is increased in tumors inCcr2/hosts compared toC57BL/6wild-type hosts as determined by perfusionwith tomato lectin (mean ± SEM, p =
0.005, Student’s t test; analysis of 12 tumors from six mice per genotype and 5–10 fields of view per tumor).
(G) The total volume of leaky vasculature does not differ between tumors inCcr2/ and C57BL/6 hosts (mean ± SEM; n.s., Student’s t test; analysis of 12 tumors
from six mice per genotype and 5–10 FOV per tumor).
(H) Relative leaky vasculature is decreased in tumors of Ccr2/hosts compared to C57BL/6 hosts as determined by the percentage of the vasculature that is
positive for Ricinus communis agglutinin I (mean ± SEM, p = 0.01, Student’s t test; analysis of 12 tumors from six mice per genotype and 5–10 FOV per tumor).
Also see Figure S7.
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histone H3) or by fluorescence intensity with Volocity software (PerkinElmer;
for F4/80, phospho-VE-cadherin, aSMA, and CD31).In Vitro Drug Sensitivity
Tumor lesions were isolated fromMMTV-PyMT;ACTB-ECFPmice using a fluo-
rescent dissection microscope, and primary mammary organoids wereCancer Cell 21, 488–503, April 17, 2012 ª2012 Elsevier Inc. 501
Cancer Cell
Visualizing Host Contribution to Chemoresistanceisolated from different tumor stages and cultured in Growth Factor Reduced
Matrigel (BD Biosciences, San Diego, CA, USA). To determine doxorubicin
sensitivity, treatment of tumor organoids was started 72 hr after isolation. To
determine lapatinib sensitivity, single cell suspensions were generated from
tumor organoids, isolated as described previously, grown to subconfluence,
re-seeded, and treated with lapatinib (Selleck Chemicals, LLC, Houston,
TX, USA). Cell viability was measured 48 hr after the addition of drugs using
the CellTiter 96 Aqueous One Solution Cell Proliferation Assay (Promega,
Madison, WI, USA).
For further experimental details, see Supplemental Experimental
Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, nine movies, and Supple-
mental Experimental Procedures and can be found with this article online at
doi:10.1016/j.ccr.2012.02.017.
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